Navigation Links
Study Presented at ACC Shows Treatment With ISIS 301012 Added to,Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C,Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C,Levels of Less Than 70 mg/dL

of less than 70 mg/dL. For Moderately High-Risk patients, the target is less than 130 mg/dL. Over 20 million people in the U.S. in the High-Risk and Moderately High-Risk categories are failing to meet recommended LDL-C targets using currently available lipid-lowering therapies.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding the development, activity, therapeutic potential and safety of ISIS 301012 in treating high cholesterol. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a b
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
(Date:12/22/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ... Self-monitoring Blood Glucose Market" report to their offering. ... This market insight focuses on the developments in the ... States . Reimbursement analysis and the effects of ... more than 73 SMBG meters have been performed, based ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
(Date:12/24/2014)... Over 700 toys, that’s what ... That is 700 smiling little faces this holiday that ... $6000 in monetary donations was given to the various ... expenses they incur through the year. Some of the ... Child's Haven , Shrine's Children's Hospitals, Toys for Tots ...
(Date:12/24/2014)... Dallas, TX (PRWEB) December 24, 2014 ... hormone specialist and functional medicine advocate with 30 years ... second trial to evaluate the health benefits of dietary ... January with new participants following excellent results from test ... , When asked to explain her interest in conducting ...
(Date:12/24/2014)... New York (PRWEB) December 24, 2014 ... mount in a mass tort litigation currently underway in ... reports. As of December 24, 2014, court documents ... proceeding on behalf of individuals who developed gynecomastia (male ... use. Data from the Court indicates that this represents ...
(Date:12/24/2014)... December 24, 2014 Dr. Vu Ho, ... expansion of his practice and med-spa with the addition ... growing list of cosmetic treatments and services. , “Silk ... the skin,” says Dr. Ho. “As a result it ... as wrinkles, sun spots, discolorations or blemishes.” , Similar ...
(Date:12/24/2014)... (PRWEB) December 25, 2014 Today, UWDress.com, the ... long sleeve wedding gowns, and launched a site-wide wedding gown ... long sleeve wedding gowns in a more unexpected way, the ... company are popular in the global market, and they are ... at UWDress.com are offered at discounted prices, up to 75% ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... and other medical personnel wear scrubs in the same manner ... to work. What we wear, as we all know, ... the while maintaining our professionalism. With all of the ... about making an important decision such as which scrubs to ...
... There has been enormous public controversy over the piece ... President,s stimulus bill. Betsy McCaughey, Ph.D. states:1) ... National Coordinator of Health Information Technology was created by ... service for doctors and hospitals that voluntarily adopted electronic ...
... Cambrex Corporation (NYSE: CBM ) reports fourth quarter and ... , ... sales decreased 3.7% excluding the impact of foreign currency. Reported ... respectively. , Adjusted EBITDA (see ...
... 11 Cell Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announced ... governs the trading of the Company,s common stock on ... of the Company,s shares in,Italy on February 10th. ... the Borsa,Italiana, the security has additionally been halted on ...
... LCAV ) today announced that it has received an ... Based on the date of this consent, the,expiration ... 2009. The,Company will issue another press release if ... LCA-Vision filed its Definitive Consent Revocation ...
... Doctors with Plastic Surgery Services of Fredericksburg ... area to offer LATISSE(TM), the new FDA-approved prescription ... darker, fuller and longer. LATISSE,s maker, Allergan, ... BOTOX(R) and Juvederm(TM). The active ingredient in LATISSE(TM) ...
Cached Medicine News:Health News:So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs 2Health News:So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs 3Health News:Betsy McCaughey Responds to Poorly Informed Critics 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 2Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 3Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 4Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 5Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 6Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 7Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 8Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 9Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 10Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 11Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 12Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 13Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 14Health News:Cambrex Reports Fourth Quarter and Full Year 2008 Results 15Health News:Cell Therapeutics Updates Shareholders on Trading 2Health News:Cell Therapeutics Updates Shareholders on Trading 3Health News:LCA-Vision Announces Consent Solicitation Deadline; Urges Stockholders to Return Gold Consent Revocation Card 2Health News:LCA-Vision Announces Consent Solicitation Deadline; Urges Stockholders to Return Gold Consent Revocation Card 3Health News:Long and Lovely Lashes by LATISSE(TM) Now Available Through Plastic Surgery Services of Fredericksburg 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: